Massachusetts Financial Services Co. MA Raises Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Massachusetts Financial Services Co. MA lifted its holdings in Immunocore Holdings plc (NASDAQ:IMCRFree Report) by 0.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 312,608 shares of the company’s stock after acquiring an additional 261 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.64% of Immunocore worth $21,357,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Exchange Traded Concepts LLC lifted its position in shares of Immunocore by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 2,656 shares of the company’s stock worth $181,000 after purchasing an additional 674 shares in the last quarter. JGP Global Gestao de Recursos Ltda. purchased a new stake in Immunocore during the 4th quarter worth approximately $230,000. China Universal Asset Management Co. Ltd. raised its position in shares of Immunocore by 366.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,900 shares of the company’s stock valued at $266,000 after purchasing an additional 3,064 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its stake in shares of Immunocore by 26.6% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 7,491 shares of the company’s stock valued at $389,000 after buying an additional 1,572 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in shares of Immunocore during the third quarter worth approximately $411,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Stock Performance

NASDAQ IMCR opened at $53.29 on Friday. Immunocore Holdings plc has a 1 year low of $42.21 and a 1 year high of $76.98. The business’s fifty day moving average is $59.59 and its two-hundred day moving average is $61.90. The company has a quick ratio of 5.94, a current ratio of 5.96 and a debt-to-equity ratio of 1.22.

Immunocore (NASDAQ:IMCRGet Free Report) last announced its earnings results on Wednesday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.12). The company had revenue of $70.30 million for the quarter, compared to analysts’ expectations of $70.72 million. Immunocore had a negative net margin of 22.60% and a negative return on equity of 16.54%. The company’s revenue for the quarter was up 27.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.35) earnings per share. On average, analysts forecast that Immunocore Holdings plc will post -1.88 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Canaccord Genuity Group boosted their target price on shares of Immunocore from $63.00 to $67.00 and gave the stock a “hold” rating in a research report on Thursday, May 9th. HC Wainwright upped their price objective on Immunocore from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. SVB Leerink started coverage on Immunocore in a report on Monday, April 29th. They issued an “outperform” rating and a $74.00 price target for the company. JPMorgan Chase & Co. upped their price target on Immunocore from $60.00 to $70.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Finally, Mizuho lowered their target price on shares of Immunocore from $90.00 to $88.00 and set a “buy” rating for the company in a research note on Monday, May 13th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, Immunocore presently has an average rating of “Moderate Buy” and an average price target of $81.85.

Get Our Latest Stock Report on IMCR

Immunocore Company Profile

(Free Report)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

Read More

Want to see what other hedge funds are holding IMCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunocore Holdings plc (NASDAQ:IMCRFree Report).

Institutional Ownership by Quarter for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.